Compare Boston Scientific Corporation (BSX) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Qurate Retail Inc Series A — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while Qurate Retail Inc Series A trades at $0.09 (market cap $1.05M). The key difference: Boston Scientific Corporation is far larger — about 63209.5× Qurate Retail Inc Series A's market cap. Which is the better fit depends on your goals.
| BSX | QVCAQ | |
|---|---|---|
Market Cap | $66.37B | $1.05M |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $15.03 |
52-Week Low | $42.63 | $0.07 |
Enterprise Value | $75.94B | $4.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
QVCAQ trades at $0.082, down 9.99% today, with a bearish technical outlook showing 13 sell signals versus 3 buy signals. Fundamentally, the company reported a net loss of $2.44 billion in 2025 on $9.23 billion revenue, with negative shareholder equity of $971 million and concerning debt-to-asset ratio of 77.57%. Recent earnings show volatility with one beat and three misses in the last four quarters.
The stock faces significant headwinds from persistent losses, negative equity, and high leverage. While QVC's recent brand celebration shows ongoing operations, the financial deterioration and bearish technical indicators suggest caution. Recovery depends on sustainable profitability improvement and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
